Physician profile
Baolin Fan
NPI 1568568897
$6,909.52
in general payments reported to CMS, 2019-2025
35 companies · $602 in 2025
The $602 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $1,122 · 2021: $1,299 · 2022: $1,339 · 2023: $967 · 2024: $629 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,178 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,178.39 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $801.65 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $665.64 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $646.61 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $571.11 | 2019-2024 | Veozah, Myrbetriq |
| Sunovion Pharmaceuticals INC. | $528.19 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $436.80 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $295.36 | 2021-2025 | |
| Glaxosmithkline, LLC. | $279.08 | 2021-2025 | Arexvy |
| Abbvie INC. | $259.40 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $244.97 | 2019-2025 | Rexulti, Nuedexta |
| Lilly USA, LLC | $227.35 | 2019-2025 | Zepbound, Mounjaro |
| Biogen, INC. | $192.12 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $187.19 | 2024-2025 | Zenpep |
| Allergan, INC. | $175.68 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $158.85 | 2023-2024 | Aptiom, Gemtesa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $151.76 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $140.84 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amarin Pharma, INC. | $115.99 | 2020-2021 | |
| Amgen INC. | $100.20 | 2020-2025 | Repatha, Otezla, Repatha |
| Nestle Healthcare Nutrition INC. | $89.57 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $83.65 | 2021 | |
| Pfizer INC. | $80.34 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $79.81 | 2019-2021 | |
| Exact Sciences Corporation | $65.63 | 2024-2025 | Cologuard Collection Kit |
| Eisai INC. | $65.11 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $49.96 | 2019-2023 | |
| Ucb, INC. | $43.18 | 2020-2022 | |
| Boston Scientific Corporation | $34.55 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $29.36 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $21.03 | 2022 | |
| Ardelyx, INC. | $20.28 | 2024 | Ibsrela |
| Gilead Sciences, INC. | $19.45 | 2023 | |
| Paratek Pharmaceuticals, INC. | $17.58 | 2024 | Nuzyra |
| Neurelis, INC. | $15.73 | 2023 | Valtoco |
| Hikma Pharmaceuticals USA | $15.50 | 2023 | Ryaltris, Mitigare |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baolin Fan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.